Q-omics provides the consensus-scored CALML3 profile across patient tissues and cancer cell-line models. CALML3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CALML3 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, CALML3 protein abundance shows 15,571 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, KIRP, and GBM as cancer lineages where CALML3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CALML3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CALML3 survival associations across molecular data types. CALML3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CALML3 RNA expression–survival associations across cancer types. High CALML3 expression shows unfavorable associations in SKCM and GBM, but favorable associations in BRCA, LGG, LUSC and CESC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CALML3 RNA expression.
This table summarizes CALML3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CALML3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CALML3 shows lower tumor expression in KIRP, KIRC, KICH and BRCA and higher tumor expression in LUSC and COAD. The KIRP box plot shows higher CALML3 RNA expression in normal versus tumor tissue (log2 FC = −3.710, t-test p < 0.001).
This table shows molecular features associated with CALML3 in patient tissues and cancer cell lines. In patient samples, CALML3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CALML3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
